Eplerenone shown to reduce cumulative heart failure hospitalisations

[News]

Pfizer Inc. (NYSE: PFE) announced results from a new post-hoc analysis of the EMPHASIS-HF trial showing statistically significant reductions in rates of cumulative heart failure (HF) hospitalisations in patients with HF treated with eplerenone compared with placebo on a background of standard optimal therapy.1 The results were presented at The European Society of Cardiology Congress (ESC) in Munich.

More... (http://www.news-medical.net/news/20120828/Eplerenone-shown-to-reduce-cumulative-heart-failure-hospitalisations.aspx)